Canada - fransk - Health Canada

pharmascience inc - propionate de fluticasone; salmétérol (xinafoate de salmétérol) - poudre - 100mcg; 50mcg - propionate de fluticasone 100mcg; salmétérol (xinafoate de salmétérol) 50mcg - adrenals

Canada - fransk - Health Canada

pharmascience inc - propionate de fluticasone; salmétérol (xinafoate de salmétérol) - poudre - 250mcg; 50mcg - propionate de fluticasone 250mcg; salmétérol (xinafoate de salmétérol) 50mcg - adrenals

Canada - fransk - Health Canada

pharmascience inc - propionate de fluticasone; salmétérol (xinafoate de salmétérol) - poudre - 500mcg; 50mcg - propionate de fluticasone 500mcg; salmétérol (xinafoate de salmétérol) 50mcg - adrenals

Irland - engelsk - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/250 microgram(s)/dose - salmeterol and fluticasone

Irland - engelsk - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/50 microgram(s)/dose - salmeterol and fluticasone

Irland - engelsk - HPRA (Health Products Regulatory Authority)

generics (uk) limited - salmeterol xinafoate ; fluticasone propionate - pressurised inhalation suspension - 25mcg/125 microgram - salmeterol and fluticasone

Irland - engelsk - HPRA (Health Products Regulatory Authority)

generics (uk) limited - salmeterol xinafoate ; fluticasone propionate - pressurised inhalation suspension - 25mcg/250 microgram - salmeterol and fluticasone

USA - engelsk - NLM (National Library of Medicine)

prasco laboratories - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u), salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - fluticasone propionate/salmeterol diskus is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. fluticasone propionate/salmeterol diskus should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use fluticasone propionate/salmeterol diskus is not indicated for the relief of acute bronchospasm. fluticasone propionate/salmeterol diskus inhalation powder 250/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. fluticasone propionate/salmeterol diskus inhalation powder 250/50 mcg is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. fluticasone propionate/salmeterol diskus inhalation po

Irland - engelsk - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/100 microgram(s) - salmeterol and fluticasone

Irland - engelsk - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/250 microgram(s) - salmeterol and fluticasone